Efficacy of this combination has been demonstrated in a number of other pre-clinical models, including MC38 colon carcinoma (109, 110), MMTV-Her2 breast cancer (108), EMT6 (109), as well as AT3-OVA breast cancer with the addition of a PI3K inhibitor (113). Here, ERBB2 is linked to breast cancer.